Transcatheter Tricuspid Valve-In-Valve Implantation in Patients with Tricuspid Bioprosthetic Valve Degeneration at High Surgical Risk: A Multicenter Case Series

Uri Landes MD1, Arthur Kerner MD4, Amit Segev MD2, Haim Danenberg MD5, Yaron Shapira MD1, Ariel Finkelstein MD3 and Ran Kornowski MD FESC FACC1

1Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel
2Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel
3Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
4Department of Cardiology, Rambam Health Care Campus, Haifa, Israel
5Department of Cardiology, Hadassah-Hebrew University Medical School, Jerusalem, Israel

ABSTRACT: Background: Transcatheter tricuspid valve-in-valve implantation (TVIV) is an attractive yet under-explored alternative to redo valve surgery. Objectives: To report the multicenter TVIV experience in Israel. Methods: We approached multiple centers and collected data regarding seven TVIV cases. Results: The study group comprised seven participants: five females and two males, with a mean age of 63 ± 12 years and EuroSCORE-II 13.6 ± 3.3%. Follow-up ranged from 3 to 21 months (mean 8 ± 6 months). All presented with advanced heart failure. The indication for valve intervention was a predominant tricuspid stenosis in three patients, significant tricuspid regurgitation in one and a mixture in three. Six procedures were conducted via a transfemoral approach and one by transatrial access. The Edwards SAPIEN™ XT valve was used in four cases and the SAPIEN™ 3 in three. Without pre-stenting/rapid pacing, all participants underwent successful valve implantation. Mean transvalvular gradient decreased from 11 ± 3 mmHg to 6 ± 3 mmHg (P = 0.003) and regurgitation decreased from moderate/severe (in four cases) to none/trace (in six of the seven cases). One patient remained severely symptomatic and died 3.5 months after the implantation. All others achieved a functional capacity improvement and amelioration of symptoms soon after the implantation, which persisted during follow-up. Conclusions: TVIV may be a safe and effective strategy to treat carefully selected patients with degenerated bioprosthetic tricuspid valve at high operative risk.

KEY WORDS: transcatheter heart valve, valve-in-valve (VIV), tricuspid, degenerated bioprosthesis

Contemporary guidelines support the growing practice of tricuspid valve surgery [1-3]. To reduce the risk of valve thrombosis, bioprosthetics are used in most tricuspid valve replacement surgeries with the inevitable risk of subsequent prosthetic valve degeneration. Redo valve surgery has been the standard of care for significant prosthetic valve degeneration; however, particularly for the tricuspid valve, it is associated with high morbidity and mortality rates [4]. Transcatheter tricuspid valve-in-valve implantation (TVIV) may be an attractive alternative to redo valve surgery, yet it is an under-explored treatment option and rather exceptional compared to valve-in-valve (VIV) implantation within degenerated aortic bioprostheses. Recent reviews of the literature [3,5] identified only a limited number of reports on TVIV, which frequently targeted young patients with congenital heart disease. In this study, we report our preliminary multicenter experience with TVIV in adult patients with acquired valvar disease.

PATIENTS AND METHODS

A datasheet was distributed to five centers in central Israel that are involved in high volume transcatheter valve therapies and have performed TVIV. Data on demographics, clinical status and co-morbidities, echocardiographic measures, procedure techniques and hemodynamic details, results, and follow-up were collected for each patient. Continuous variables are presented as means and standard deviations (SD) or medians and interquartile ranges (IQR). Paired t-tests and Wilcoxon tests were used to compare pre- and post-procedure valvular gradients within patients. A two-tailed P < 0.05 was considered statistically significant.
RESULTS

BASELINE CHARACTERISTICS

Seven patients were identified and included in the current analysis. Their mean age was 63 ± 12 years; five were female, and the mean EuroSCORE II was 13.6 ± 3.3%. Six patients presented with advanced heart failure symptoms, namely New York Heart Association (NYHA) functional class III-IV, while one patient presented with moderate symptoms (NYHA II). All had left ventricular ejection fraction ≥ preserved (57 ± 6%). Three patients had two prior cardiac surgeries, all had prosthetic mitral valves, and one patient also had aortic and pulmonary prosthetic valves. Severe pulmonary hypertension was present in the four patients with an echocardiographic measurable pulmonary blood pressure, atrial fibrillation was present in six, renal insufficiency in two and liver cirrhosis (secondary to right heart failure) in two patients. The mean daily furosemide dose (intravenous) at admission was 150 ± 18 mg.

TRICUSPID VALVE CHARACTERISTICS

At baseline, the mean gradient over the tricuspid valve was 11 ± 3 mmHg and four patients had tricuspid valve regurgitation ≥ moderate (assessed by echocardiography). The indication for tricuspid valve intervention was a predominant tricuspid stenosis (defined as mean gradient > 5 mmHg) in three patients, a significant (≥ moderate) tricuspid regurgitation in one patient, and a mixture of both pathologies in three. Some of their baseline characteristics are described in Table 1.

After a multidisciplinary discussion of each case, a “standard” reoperation was overruled by the heart teams due to an estimated extremely high operative risk. Given patients’ advanced symptoms, the transcatheter intervention was estimated to provide the utmost efficacy-safety profile. Consequentially, all patients gave their informed consent and were referred for TVIV.

PROCEDURAL AND IN-HOSPITAL OUTCOMES

All procedures were conducted between 2014 and 2016 via a transfemoral vein access, except for one that was conducted by a transatrial access in 2011. General anesthesia was used in four cases and conscious sedation in three. Pre-dilatation using a high pressure balloon was performed in three of six patients with significant tricuspid stenosis (using 20 mm, 24 mm, and 25 mm balloons). Five procedures were done under transesophageal, one under transthoracic, and one under intracardiac echocardiographic guidance. The Edwards SAPIENTM XT valve (26 or 29 mm, Edwards Lifesciences, Irvine, CA, USA) was used in four cases and the SAPIENTM 3 (29 mm, Edwards Lifesciences) in three. Without pre-stenting and without rapid pacing, all patients underwent a successful valve implantation. Figure 1 A to D (top panel) demonstrates the intraprocedural fluoroscopy of some TVIV procedure key steps. Figure 1 A to C (bottom panel) shows the fluoroscopy of a patient (index no. 5) who underwent a combined transapical mitral and transfemoral TVIV implantation.

Table 1. Patients’ demographic and historical data

<table>
<thead>
<tr>
<th>Case</th>
<th>Center</th>
<th>Age</th>
<th>Gender</th>
<th>NYHA class</th>
<th>Native TV pathology</th>
<th>No. of prior surgeries</th>
<th>Years since TV surgery</th>
<th>Indication for TV surgery</th>
<th>Bioprosthesis TV size (mm)</th>
<th>Bioprosthesis TV type</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Hadassah</td>
<td>63</td>
<td>M</td>
<td>2</td>
<td>Rheumatic</td>
<td>1</td>
<td>8</td>
<td>Mixed</td>
<td>29</td>
<td>Unknown</td>
</tr>
<tr>
<td>2</td>
<td>Sheba</td>
<td>39</td>
<td>F</td>
<td>3</td>
<td>Rheumatic</td>
<td>2</td>
<td>13</td>
<td>Mixed</td>
<td>29</td>
<td>Edwards</td>
</tr>
<tr>
<td>3</td>
<td>Tel Aviv Sourasky</td>
<td>60</td>
<td>F</td>
<td>4</td>
<td>Rheumatic</td>
<td>2</td>
<td>20</td>
<td>Mixed</td>
<td>29</td>
<td>No-react</td>
</tr>
<tr>
<td>4</td>
<td>Rambam</td>
<td>65</td>
<td>F</td>
<td>4</td>
<td>Rheumatic</td>
<td>1</td>
<td>40</td>
<td>Stenosis</td>
<td>27</td>
<td>Unknown</td>
</tr>
<tr>
<td>5</td>
<td>Rambam</td>
<td>72</td>
<td>M</td>
<td>4</td>
<td>Mxomatous</td>
<td>1</td>
<td>14</td>
<td>Mixed</td>
<td>31</td>
<td>Perimount</td>
</tr>
<tr>
<td>6</td>
<td>Rabin</td>
<td>78</td>
<td>F</td>
<td>3</td>
<td>Rheumatic</td>
<td>2</td>
<td>37</td>
<td>Mixed</td>
<td>29</td>
<td>Medtronic Hancock</td>
</tr>
<tr>
<td>7</td>
<td>Rabin</td>
<td>64</td>
<td>F</td>
<td>4</td>
<td>Rheumatic</td>
<td>1</td>
<td>11</td>
<td>Mixed</td>
<td>33</td>
<td>Carpenter Edwards</td>
</tr>
</tbody>
</table>

NYHA = New York Heart Association, TV = tricuspid valve, Mixed = stenosis (≥ moderate) and regurgitate (≥ moderate)

Figure 1. Intraprocedural fluoroscopy.
Top panel:
[A, B] The transcatheter tricuspid valve (blue arrow) is being transported to its target position. [C] Without pre-stenting and pre-dilatation, balloon expansion of the valve is performed. [D] The device is well expanded and released in the correct anatomic position.

Lower panel:
Post-implantation, tricuspid valve performance was significantly improved. Table 2 summarizes the main technical details and hemodynamic results of each procedure. The mean transvalvular gradient decreased from $11 \pm 3$ mmHg to $6 \pm 3$ mmHg ($P = 0.003$) and regurgitation decreased from moderate/severe (in four patients) to none/trace in all but one who remained with a mild tricuspid regurgitation [Figure 2].

Peri-procedural complications included one major vascular complication (femoral artery perforation near the femoral vein access site) that was treated successfully with a covered stent implantation, one case of transient periprocedural bradycardia with an escape rhythm that resolved spontaneously, and one case of ventilation-associated pneumonia that was treated with antibiotics. Following the implantation, all patients received anti-thrombotic therapy with a dual antiplatelet or a single antiplatelet combined with a vitamin K antagonist (VKA) anticoagulant agent. Five patients left the hospital in a good clinical condition 5 to 10 days after the procedure, and another patient who developed pneumonia left 11 days after the procedure. The patient who underwent the transatrial TVIV left the hospital 2 weeks after the procedure while remaining in NYHA class III heart failure.

Follow-up time ranged from 3 to 21 months (mean 8 ± 6 months). After discharge, the transatrial TVIV patient remained highly symptomatic and died due to a major stroke 3.5 months later. The remaining six patients experienced a significant and persistent amelioration of symptoms and improved functional capacity until the latest follow-up visit (three patients with NYHA class I, and three with NYHA class II). One of the six patients had a major stroke a year and a half after the implantation, while demonstrating subtherapeutic international normalized ratio (INR) levels with a VKA indicated for her mechanical mitral valve and atrial fibrillation. No other major safety concerns were observed during follow-up. All repetitive transthoracic echocardiography studies so far demonstrated a consistent low and stable transvalvular gradient with absence of significant leaks.

**Table 2. Procedure technical and hemodynamic data**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Indication</th>
<th>Mean gradient (mmHg)</th>
<th>Regurgitation</th>
<th>THV type, size</th>
<th>Balloon pre-dilatation</th>
<th>Rapid pacing</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TS</td>
<td>Pre- 12, Post- 5</td>
<td>Mild</td>
<td>Mild</td>
<td>SAPIEN XT, 26 mm</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>TS+TR</td>
<td>Pre- 10, Post- 9</td>
<td>Severe</td>
<td>None</td>
<td>SAPIEN 3, 29 mm</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>TS+TR</td>
<td>Pre- 14, Post- 10</td>
<td>Moderate</td>
<td>None</td>
<td>SAPIEN XT, 29 mm</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>TS</td>
<td>Pre- 10, Post- 5</td>
<td>Severe</td>
<td>Trivial</td>
<td>SAPIEN XT, 29 mm</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>TS+TR</td>
<td>Pre- 10, Post- 5</td>
<td>Severe</td>
<td>Trivial</td>
<td>SAPIEN XT, 29 mm</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>TS</td>
<td>Pre- 12, Post- 4</td>
<td>Mild</td>
<td>None</td>
<td>SAPIEN XT, 29 mm</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>TR</td>
<td>Pre- 5, Post- 3</td>
<td>Moderate</td>
<td>Trivial</td>
<td>SAPIEN 3, 29 mm</td>
<td>No</td>
</tr>
</tbody>
</table>

RV = right ventricle, THV = transcatheter heart valve, TR = tricuspid valve regurgitation, TS = tricuspid valve stenosis

**DISCUSSION**

For many years redo surgery and valve replacement have been the standard of care for patients with significant degenerated bioprostheses in any position [1,2]. However, due to the high risk associated with reoperation, particularly in older patients with co-morbidities, TVIV implantations have emerged as an attractive alternative and are increasingly being performed. While so far preferentially implemented in the aortic position, given the difficulties in tricuspid valve surgery and the advantages of transcatheter intervention, reports on TVIV are mounting.

In the present study, one patient who underwent transatrial TVIV in 2011 remained highly symptomatic and died of a stroke 3.5 months after the implantation. Whether his death was directly or indirectly related to the TVIV remains unknown, as the time interval and the mechanism in which right heart side intervention causes stroke in the absence of right-to-left shunt are not clear, and stroke is unlikely to be related to TVIV. Nevertheless, this patient clearly did not benefit from the intervention.

The other six patients who underwent TVIV between 2014 and 2016 by a transfemoral approach experienced a significant improvement in their tricuspid valve function, accompanied by...
functional capacity progress and symptom relief soon after the implantation and during short to midterm follow-up.

Our series demonstrates that TVIV currently represents a promising treatment solution in a carefully selected group of adult patients. Since the TVIV experience is rather preliminary, we highlight some key technical reflections.

Mal-deployment and/or erroneous sizing of the transcatheter valve may cause device dysfunction, from under-expansion, increased transvalvular gradients and regurgitations to device embolization into the right ventricle or pulmonary artery, which is a major complication reported in association with TVIV [5-7]. It is known that optimal sizing and positioning of any valve inside a bioprosthetic valve necessitates understanding of the detailed structural characteristics and that the internal ring diameter of the surgical valve is the most important determinant for sizing. To date, no imaging modality has been proven superior over another in annular size valuations. Echocardiography may underestimate annular size [8], and the manufacturer’s size label mostly corresponds to the outer diameter, which is also unable to capture the temporal trends (i.e., pannus, bulky leaflets and calcifications) that might change annular size. Accordingly, at this time, a multimodality approach – systematically integrating baseline manufacturer’s diameters (offering the theoretical maximum diameter), two or three-dimensional transesophageal echocardiography, fluoroscopy and in particular computed tomography (and, in selected cases, intraprocedural balloon sizing) – contributes to TVIV sizing/planning.

Earlier case reports on TVIV commonly described pre-stenting utilization with the primary goal of reducing the internal diameter of the surgical valve and also lengthening the short landing zones in some cases. As a result, pre-stenting may also reduce the internal transcatheter valve diameter and thus contribute to a smaller orifice area, which can be detrimental in the long term. In this series, as well as in another more recent report [9], pre-stenting was no longer performed since the modern devices are available in larger sizes and enable pre-stenting-free TVIV in most cases.

Another frequently described TVIV element is rapid ventricular pacing, which similar to other transcatheter balloon-expandable valve implantations is suggested to help achieve an unwavering position during balloon inflation and valve deployment. In TVIV, to avoid jailing of a right ventricular pacing lead, rapid pacing is generally achieved using a lead positioned in the left ventricle, coronary sinus or the epicardium – each with its potential damage/safety concerns. Unlike the hemodynamics that accompany aortic valve implantation, the low pressure gradients across the tricuspid valve may permit a safe and accurate valve positioning without rapid pacing, as was demonstrated in all our cases as well as in other reports [5].

At present, TVIV has been reported to be performed using either the Melody® valve (Medtronic, Minneapolis, MN, USA) or the Edwards SAPIEN™ valve. Since the former is only available in a rather small diameter size (maximum 22 mm) it can be used effectively in young patients with congenital heart disease but is less suitable for adults with acquired valvulopathy. In our series, the diameters of the failed bioprosthetic valves ranged between 29 and 33 mm, and the transcatheter valve diameters used ranged between 26 and 29 mm. To the best of our knowledge, there is only one published case report on the utilization of SAPIEN 3 in TVIV [10].

Although our follow-up time is limited, our findings of no major safety concerns, good post-TVIV device function and regression of symptoms point to TVIV as a highly reassuring treatment strategy.

CONCLUSIONS
In this preliminary case series, TVIV was found to be safe and effective for treating a carefully selected group of adult patients with a degenerated bioprosthetic tricuspid valve, without underlying congenital heart disease, and at high operative risk. Using the Edwards SAPIEN XT or SAPIEN 3 valve, TVIV led to improvement in hemodynamics and functional status, both acutely and at short to midterm follow-up. More studies with extended follow-up are needed to verify our results and to assess durability issues.

Correspondence
Dr. U. Landes
Dept. of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva 39100, Israel
Fax: (972-3) 924-9850, e-mail: urlandes@gmail.com

References